Clarivate Epidemiology has created a robust repository of the prevalence of biomarker- and mutation-defined treatment-eligible cancer populations. Using Clarivate’s Biomarker Epidemiology, you…
Essential thrombocythemia (ET) is a hematological malignancy characterized by thrombocytosis. Patients are classified into different categories and, as such, receive different therapies and…
In June 2021, Biogen / Eisai’s anti-Aβ MAb aducanumab (Aduhelm) received accelerated approval from the FDA for the treatment of Alzheimer’s Disease (AD), rendering it the first potential DMT…
DRG Epidemiology’s coverage of sickle cell disease (SCD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets in North America and Europe (…
Approved therapies for Alzheimer's disease (AD) comprise symptomatic agents (e.g., donepezil, memantine) that provide only modest cognitive benefit for a limited period of time. A rapidly…
Clarivate’s Epidemiology's coverage of retinal vein occlusion comprises epidemiological estimates of key patient populations. We report the prevalence of retinal vein occlusion for each…
DRG Epidemiology’s coverage of atrial fibrillation comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of atrial fibrillation for…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key hereditary angioedema patient populations covering 171 countries and…
Clarivate Epidemiology’s coverage of hereditary angioedema (HAE) comprises epidemiological estimates of key patient populations in 45 countries. We report the prevalence of HAE for each country,…
DRG Epidemiology’s coverage of atrial fibrillation comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of atrial fibrillation for…
Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by varying degrees of hair loss due to the targeting of anagen hair follicles by the host immune system. The primary…
The treatment of newly diagnosed metastatic hormone-sensitive prostate cancer has evolved in recent years with the approval of hormonal agents such as Zytiga (Janssen), Xtandi (Pfizer / Astellas),…
Clarivate Epidemiology’s coverage of PV comprises epidemiological estimates of key patient populations in the major European pharmaceutical markets (Austria, Belgium, Czech Republic, Denmark,…
Clarivate Epidemiology's coverage of Pemphigus vulgaris comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of Pemphigus…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Pemphigus vulgaris patient population covering 171 countries and…